EA200870167A1 - Димерные соединения - агонисты рецепторов fgf (fgfr), способ их получения и их применение в терапии - Google Patents

Димерные соединения - агонисты рецепторов fgf (fgfr), способ их получения и их применение в терапии

Info

Publication number
EA200870167A1
EA200870167A1 EA200870167A EA200870167A EA200870167A1 EA 200870167 A1 EA200870167 A1 EA 200870167A1 EA 200870167 A EA200870167 A EA 200870167A EA 200870167 A EA200870167 A EA 200870167A EA 200870167 A1 EA200870167 A1 EA 200870167A1
Authority
EA
Eurasian Patent Office
Prior art keywords
therapy
receptor agonists
fgfr
fgf receptor
reception
Prior art date
Application number
EA200870167A
Other languages
English (en)
Other versions
EA015046B1 (ru
Inventor
Франсуаз Боно
Натали Гийо
Жан-Пьер Маффран
Пьер Фон
Якоб-Альсбок Ольсен
Жиль Анн-Аршар
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of EA200870167A1 publication Critical patent/EA200870167A1/ru
Publication of EA015046B1 publication Critical patent/EA015046B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Соединения - агонисты рецепторов FGF, отвечающие общей формуле M-L-M, в которой Mили М, одинаковые или разные, каждый независимо друг от друга, означает мономерное звено М, и L означает связывающую группу, которая ковалентно связывает Mи М, причем указанное мономерное звено М отвечает следующей общей формуле (I):Способ получения и применение в терапии.
EA200870167A 2006-01-13 2007-01-12 Димерные соединения - агонисты рецепторов fgf (fgfr), способ их получения и их применение в терапии EA015046B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0600317A FR2896247B1 (fr) 2006-01-13 2006-01-13 Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
PCT/FR2007/000051 WO2007080325A1 (fr) 2006-01-13 2007-01-12 Composes dimeres agonistes des recepteurs des fgfs

Publications (2)

Publication Number Publication Date
EA200870167A1 true EA200870167A1 (ru) 2009-12-30
EA015046B1 EA015046B1 (ru) 2011-04-29

Family

ID=36808846

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870167A EA015046B1 (ru) 2006-01-13 2007-01-12 Димерные соединения - агонисты рецепторов fgf (fgfr), способ их получения и их применение в терапии

Country Status (37)

Country Link
US (1) US9120819B2 (ru)
EP (1) EP2018165B1 (ru)
JP (1) JP5286088B2 (ru)
KR (1) KR101378220B1 (ru)
CN (1) CN101384258B (ru)
AR (1) AR059001A1 (ru)
AT (1) ATE505188T1 (ru)
AU (1) AU2007204252B2 (ru)
BR (1) BRPI0707132A2 (ru)
CA (1) CA2633057C (ru)
CR (1) CR10097A (ru)
CY (1) CY1111688T1 (ru)
DE (1) DE602007013889D1 (ru)
DK (1) DK2018165T3 (ru)
EA (1) EA015046B1 (ru)
EC (1) ECSP088592A (ru)
ES (1) ES2364857T3 (ru)
FR (1) FR2896247B1 (ru)
HK (1) HK1130009A1 (ru)
HN (1) HN2008001067A (ru)
HR (1) HRP20110514T1 (ru)
IL (1) IL192403A (ru)
JO (1) JO2659B1 (ru)
MA (1) MA30214B1 (ru)
MX (1) MX2008009010A (ru)
NO (1) NO20083406L (ru)
NZ (1) NZ569631A (ru)
PE (1) PE20071115A1 (ru)
PL (1) PL2018165T3 (ru)
PT (1) PT2018165E (ru)
RS (1) RS51872B (ru)
SI (1) SI2018165T1 (ru)
TN (1) TNSN08250A1 (ru)
TW (1) TWI386408B (ru)
UA (1) UA95469C2 (ru)
WO (1) WO2007080325A1 (ru)
ZA (1) ZA200806547B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2883286B1 (fr) * 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
EP2270043A1 (en) 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
FR2962438B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
FR2962437B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
US8901341B2 (en) * 2011-02-11 2014-12-02 Bezwada Biomedical, Llc Amino acid derivatives and absorbable polymers therefrom
WO2012167261A2 (en) 2011-06-03 2012-12-06 Yale University Compositions and methods for treating and preventing neointimal stenosis
FR2982261B1 (fr) * 2011-11-04 2014-06-13 Galderma Res & Dev Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique
FR2985257B1 (fr) * 2011-12-28 2014-02-14 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
FR2985258A1 (fr) * 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
FR2985185B1 (fr) * 2012-01-04 2013-12-27 Sanofi Sa Utilisation en therapeutique de derives d'imidazopyridine
JP6806562B2 (ja) 2013-03-15 2021-01-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｅＩＦ２α経路の調節因子
JP2016520060A (ja) * 2013-05-06 2016-07-11 アンドリュー・ビー・ブッシュ ｉｎｖｉｖｏでの抗体産生および液性免疫のＦＧＦ調節
CA3007631A1 (en) 2015-12-11 2017-06-15 Research Institute At Nationwide Children's Hospital Optimized patient specific non-linear tissue engineered vascular grafts

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193926A (en) 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
AU2003236201A1 (en) 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
PT2018165E (pt) 2011-07-14
CN101384258B (zh) 2013-06-26
KR101378220B1 (ko) 2014-03-27
CR10097A (es) 2008-10-29
JP2009523160A (ja) 2009-06-18
DE602007013889D1 (de) 2011-05-26
ES2364857T3 (es) 2011-09-15
US20090069368A1 (en) 2009-03-12
HN2008001067A (es) 2011-01-24
BRPI0707132A2 (pt) 2011-04-19
AR059001A1 (es) 2008-03-05
US9120819B2 (en) 2015-09-01
TNSN08250A1 (en) 2009-10-30
FR2896247B1 (fr) 2008-02-29
ZA200806547B (en) 2009-12-30
TW200738708A (en) 2007-10-16
HRP20110514T1 (hr) 2011-08-31
AU2007204252A1 (en) 2007-07-19
AU2007204252B2 (en) 2012-05-24
PE20071115A1 (es) 2007-12-14
CN101384258A (zh) 2009-03-11
EA015046B1 (ru) 2011-04-29
ECSP088592A (es) 2008-08-29
JP5286088B2 (ja) 2013-09-11
CA2633057C (fr) 2014-10-21
MA30214B1 (fr) 2009-02-02
JO2659B1 (en) 2012-06-17
EP2018165B1 (fr) 2011-04-13
HK1130009A1 (en) 2009-12-18
PL2018165T3 (pl) 2011-09-30
DK2018165T3 (da) 2011-08-01
CA2633057A1 (fr) 2007-07-19
WO2007080325A1 (fr) 2007-07-19
NO20083406L (no) 2008-10-13
RS51872B (en) 2012-02-29
ATE505188T1 (de) 2011-04-15
FR2896247A1 (fr) 2007-07-20
IL192403A (en) 2012-10-31
EP2018165A1 (fr) 2009-01-28
KR20090006060A (ko) 2009-01-14
CY1111688T1 (el) 2015-10-07
WO2007080325A8 (fr) 2008-10-23
IL192403A0 (en) 2008-12-29
TWI386408B (zh) 2013-02-21
MX2008009010A (es) 2008-09-25
NZ569631A (en) 2011-04-29
UA95469C2 (ru) 2011-08-10
SI2018165T1 (sl) 2011-08-31

Similar Documents

Publication Publication Date Title
EA200870167A1 (ru) Димерные соединения - агонисты рецепторов fgf (fgfr), способ их получения и их применение в терапии
EA200801521A1 (ru) Лиганды, которые обладают специфичностью связывания к vegf и/или egfr, и способы их применения
CY1119696T1 (el) Cc-1065 αναλογα και τα συζευγματα αυτων
EA201401107A1 (ru) Специфические антагонисты рецептора fgf-r4
CY1118997T1 (el) Διμερεις ενωσεις αγωνιστη υποδοχεα fgf (fgfr), διαδικασια για την παρασκευη αυτων και θεραπευτικη χρηση αυτων
CY1117319T1 (el) Τρικυκλικα παραγωγα αμινης ως αναστολεις πρωτεϊνικης τυροσινης κινασης
EA201001242A1 (ru) ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
BRPI0919473A2 (pt) Agentes de ligação frizzled e usos dos mesmos
EA200801172A1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
CY1117942T1 (el) Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
GEP20125517B (en) Humanized monoclonical antibodies to hepatocyte growth factor
EA201170227A1 (ru) Имидазолкарбоксамиды
EA201390575A1 (ru) Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
EA201500156A2 (ru) Доставка антител посредством модульного домена распознавания
EA201100923A1 (ru) Антитела человека против тканевого фактора
MX356656B (es) Compuestos dimeros agonistas de los receptores de los fgf (fgfr), su procedimiento de preparacion y su uso terapeutico.
EA200970987A1 (ru) Трициклические азотсодержащие соединения в качестве антибактериальных агентов
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
AR073072A1 (es) Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
EA201000614A1 (ru) Производные пурина как лиганды аденозинового рецептора а

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU